Home Trending Stocks Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials...

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share up to USD$1.48 early on in the trading day.

Solid Liquidity Position

The company reported a stellar liquidity position at the end of the fourth quarter of fiscal 2021, with cash and cash equivalents in the amount of USD$107.5 million as of March 31st, 2021. This is comparable to the USD$13.5 million reported in the prior quarter, ended December 31st, 2020. The fourth quarter of the prior fiscal year saw the company report a liquidity position of USD$26.7 million.

5 Stocks Under $10 That Are Poised to Take Off

Investing in stocks under $10 could significantly increase the returns on your portfolio, especially if you pick the right stocks! Within this report you will find 5 top stocks that offer investors huge upside potential and the best bang for their buck.

Add them to your watchlist before they take off!

Get the Top 5 Stocks Now!

Sponsored

Registered Direct Offering

This massive increase is largely due to the capital generated through the company’s registered direct offering that closed on February 8th, 2021. The offering saw the company offer up to 40 million shares of its common stock, at a purchase price of USD$2.50 per share. Before the deduction of expenses related to the offering, the company generated gross proceeds amounting to USD$100 million.

Operational Cash Burn Rate

The company’s operational cash burn rate for the last quarter of the fiscal year 2021 came in at USD$5.2 million, down from the USD$5.9 million reported for the third quarter of fiscal 2021. The burn rate is largely attributable to expenses related to the clinical trials currently underway in pancreatic and sarcoma cancers. Based on the forecast of its operations, TYME expects its quarterly cash burn rate to range from USD$6.0 million to USD$8.0 million per quarter during the fiscal year 2022.

OASIS Breast Cancer Trial

June 11th, 2021 saw the company announce the OASIS breast cancer trial at Georgetown University. The trial is an investigator-initiated prospective open-label Phase 2 Trial that is designed to evaluate the efficacy and safety of SM-88 for the treatment of metastatic hormone receptor positive, human epidermal growth factor receptor 2 negative breast cancer after treatment with a CDK4/6 inhibitor.

Details of the Trial

The trial consists of two stages, with an initial enrolment of 30 patients that would eventually be expanded to include a total of 50 patients without standard background therapies. The primary endpoint of the trial is RECIST tumor response, with the collection of cell-free DNA from patients being carried out several times throughout the treatment.

Future Outlook for TYME

Armed with a solid liquidity position, TYME is poised to capitalize on the progress being made in the commercialization of its pipeline. Current and potential investors are hopeful that management will continue to leverage the resources at their disposal to facilitate significant and sustained increases in shareholder value.

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Must Read

Tyme Technologies, Inc. (TYME) Stock Trends downwards Following Strong Q4 2021 Financials and Progress in OASIS Trial

Tyme Technologies, Inc. (TYME) stock prices was down by -6.92% shortly after market trading commenced on June 11th, 2021, bringing the price per share...

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Magnachip Semiconductor Corporation (MX) stock is Popping High today: Why is it so?

Shares of the Magnachip Semiconductor Corporation (MX) stock were popping high after the announcement of its receival of unsolicited buyout bid from Cornucopia Investment...

Why is Autolus Therapeutics plc (AUTL) stock rising today?

Shares of  Autolus Therapeutics plc (AUTL) stock were rising today on June 11, 2021, following the release of the presentation data related to obe-cel...

Mustang Bio, Inc. (MBIO) stock is climbing today: Here is to know why.

Mustang Bio, Inc. (MBIO) stock announced the updated interim data from Phase 1/2 clinical trial of its MB-106 CD20-targeted, autologous CAR T today on...

Related News

Prophase Labs Inc. (PRPH) stock surged during pre-market trading session. Let’s figure out why?

Prophase Labs Inc. (NASDAQ: PRPH) stock soared by 5.87% at last close as well as the PRPH stock price has been observed rising by...

Why Surgalign Holdings, Inc. (SRGA) stock is gloomy today?

Surgalign Holdings, Inc. (SRGA) stock announced the $50 million registered direct offering priced at the market under Nasdaq rules today on June 10, 2021,...

Exela Technologies Inc. (XELA) stock soars during pre-market. Here’s what you should know?

Exela Technologies Inc. (NASDAQ: XELA) stock gained by 8.28% at last close while the XELA stock price rises in the pre-market as well, by...

Atossa Therapeutics, Inc. (ATOS) stock gains during pre-market trading. Here’s to know why?

Atossa Therapeutics, Inc. (NASDAQ: ATOS) stock declined by 27.51% at the last close while the ATOS stock price rises further by 9.09% in the...

Root, Inc. (ROOT) Stock Surges After Becoming Latest Target of Meme Stock Phenomenon Gripping the Market

Root, Inc. (ROOT) stock prices were up by a significant 20.87% shortly after market trading commenced on June 9th, 2021, bringing the price per...

LEAVE A REPLY

Please enter your comment!
Please enter your name here

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

Get The Best Stocks To Trade Every Day!

Join now to get the NewsHeater.com pre-market morning brief 100% free

We do not sell or share your information with anyone.

Get Notified Of Insider Trades, Analyst Upgrades & Downgrades, Earnings Updates & Best Stocks To Trade Every Single Morning

100% free. stop anytime no spam